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In this study the mRNA levels of ﬁve EGFR indirectly related genes, EGFR, HB-EGF, ADAM17, PTEN,a n dMMP9,h a v eb e e n
assessed by Real-time PCR in a panel of 37 glioblastoma multiforme specimens and in 5 normal brain samples; as a result, in
glioblastoma,ADAM17 andPTEN expressionwassigniﬁcantlylowerthaninnormalbrainsamples,and,inparticular,astatistically
signiﬁcant inverse correlation was found between PTEN and MMP9 mRNA levels. To verify if this correlation was conserved in
gliomas,PTEN and MMP9 expression was further investigated in an additional panel of 16 anaplastic astrocytoma specimens and,
inparallel,indiﬀerenthumannormalandastrocytictumorcelllines.InanaplasticastrocytomasPTEN expressionwassigniﬁcantly
higher than in glioblastoma multiforme, but no signiﬁcant correlation was found between PTEN and MMP9 expression. PTEN
and MMP9 mRNA levels were also employed to identify subgroups of specimens within the diﬀerent glioma malignancy grades
and to deﬁne a gene expression-based diagnostic classiﬁcation scheme. In conclusion, this gene expression survey highlighted that
the combined measurement of PTEN and MMP9 transcripts might represent a novel reliable tool for the diﬀerential diagnosis of
high-grade gliomas, and it also suggested a functional link involving these genes in glial tumors.
Copyright © 2009 Sergio Comincini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Glioblastoma multiforme is the most malignant brain tumor
among astrocytic gliomas with a typical prognosis of about
12 months in spite of current therapeutic approaches that
include neurosurgery followed by combined chemotherapy
and radiotherapy [1]. Recently, the development of massive
screening genome technologies, such as gene expression
proﬁling, has prompted new attempts to the classiﬁcation
of glioblastoma subgroups on molecular basis in order to
identify new diagnostic or prognostic tools. At present the
search for potential molecular markers among aberrant
signal transduction pathways in glioblastoma is actively
exploited for the optimization of existing therapies or
the development of innovative drugs [2]. However, the
accomplishment of this ambitious task is severely hindered
by the extreme heterogeneity of glioblastoma tumor samples
and by the subsequent variability of possibly identiﬁed
molecular markers. One way to overcome this limit could
be represented by the concomitant analysis of the mRNA
expression of several selected genes, already known to be
functionally involved in the cellular malignant transfor-
mation. This analysis could highlight diﬀerences in gene
expression levels among high-grade gliomas, or at the same
time it could reveal relationships within glioma subtypes
between the genes analyzed in order to improve their
reliability as prognostic or diagnostic markers.
The epidermal growth factor (EGF) receptor (EGFR or
ErbB1) plays a pivotal role in cancer physiology because
its activation, elicited by at least six diﬀerent endoge-
nous peptidergic EGF-like ligands, leads to the activa-
tion of intracellular signalling pathways that modulate cell2 Journal of Biomedicine and Biotechnology
Table 1: Age, gender, mRNA expression values (in femptograms), and anatomical location of glioblasytoma multiforme samples.
Age Sex EGFR ADAM17 HB-EGF PTEN MMP9 Location
68 M 2.78 0.31 0.69 1.85 6.39 Parietal
84 F 155.97 0.31 4.43 6.81 31.13 Parietal
23 M 95.25 3.54 19.01 5.15 0.04 Cerebellum
50 M 579.69 0.87 9.28 8.97 43.32 Frontal dx
71 F 7.11 0.08 0.82 2.27 0.21 Frontal dx
58 M 236.18 0.91 8.98 15.05 183.29 Parietal dx
66 M 12.85 0.13 1.38 0.41 0.04 Temporal sx
50 M 150.97 3.08 4.87 1.65 3.09 Temporal dx
38 F 60.10 2.23 9.23 7.01 30.41 Occipital dx
61 F 2.88 0.41 1.75 1.96 0.72 Frontal sx
68 F 4.87 0.63 8.71 0.82 0.82 Occipital dx
70 M 23.38 2.13 2.82 3.92 3.51 Frontal dx
59 M 425.51 1.28 4.32 4.84 8.04 Frontal sx
67 F 1268.24 2.99 13.92 12.68 32.58 Temporal dx
31 M 13.33 1.87 52.08 6.66 13.33 Frontal sx
68 F 0.77 0.59 12.85 0.62 1.04 Parietal dx
39 F 6.87 13.33 0.21 3.14 0.16 Frontoinsular
39 M 2.37 0.42 3.96 4.79 0.21 Parietal sx
45 F 274.74 0.66 7.14 1.25 2.52 Frontal dx
63 M 1284.37 13.33 0.21 3.12 10.62 Temporal dx
71 M 30.11 5.42 10.62 2.92 2.08 Frontal sx
60 M 73.96 17.71 7.54 3.33 4.37 Temporal sx
44 F 2562.92 6.87 18.96 3.33 8.33 Thalamus sx
73 F 38.75 13.12 7.53 3.33 1.04 Paratrigonal sx
47 F 16.88 4.79 7.29 3.13 1.04 Frontal sx
63 M 12.01 12.31 28.22 3.85 3.28 Occipital dx
77 F 239.85 8.72 22.56 2.92 6.31 Cortical anterior
55 F 22.36 2.51 5.38 1.54 0.05 Parietal dx
70 F 13.18 9.18 12.31 3.08 0.16 Parietal dx
60 F 8.92 7.95 16.56 1.54 0.23 Temporal sx
54 M 1071.43 15.49 16.56 2.56 1.64 Temporal sx
55 M 371.49 9.54 19.49 1.54 1.85 Temporal sx
55 F 27.54 9.23 5.13 1.54 0.15 Temporal sx
58 M 21.38 20.87 17.38 3.08 1.23 Temporal sx
53 F 8.1 7.23 9.74 2.05 0.15 Occipital sx
69 F 4.66 12.56 26.69 3.08 1.69 Frontal sx
70 F 29.49 5.23 7.08 7.23 0.61 Parietal dx
proliferation, metastasis, and angiogenesis [3]. About 40%–
50% of glioblastoma cases are characterized by EGFR gene
ampliﬁcationoroverexpression,togetherwiththeexpression
of the mutated and constitutively active EGFR isoform
EGFRvIII [3]. Upregulation of the EGFR pathway could also
result from an increased availability of EGFR endogenous
agonists belonging to the family of EGF-like growth factors.
Heparin-binding epidermal growth factor (HB-EGF)
actsasapotentproliferativeagentinmanydiﬀerentcelltypes
via the activation of EGFR or the other EGF-like receptor
ErbB4 [4]. HB-EGF is initially synthesized as the membrane-
spanning protein proHB-EGF and then is proteolytically
cleaved by “A Disintegrin And Metalloproteinase” (ADAM)
family members that release the soluble form (sHB-EGF)
in the extracellular space. The ADAM isoform responsible
f o rt h i sp r o c e s sa p p e a r st ob ec e l lt y p ed e p e n d e n t ,s i n c ei n
diﬀerent experimental models ADAM 10, 12, and 17 have
been involved in proHB-EGF shedding [3]. The overex-
pression of ADAM17, also named “tumor necrosis factor-
alpha-converting enzyme” (TACE), seems to be involved in
the malignant potential of cancer cells [5], and, notably,
this metalloprotease modulates HB-EGF shedding and cell
proliferation in U373-MG glioblastoma cell line [5].
In the clinical practice only 10%–20% of glioblastoma
patients respond to EGFR kinase inhibitors, and this poor
response has been ascribed to a combination of EGFRJournal of Biomedicine and Biotechnology 3
Table 2: Age, gender, PTEN,a n dMMP9 expression values (in femtograms), and anatomical location of anaplastic astrocytoma samples.
Age Sex PTEN MMP9 Location
44 M 1.72 1.25 Temporal sx
68 F 7.66 0.57 Thalamus sx
67 F 2.25 37.06 Frontal dx
60 F 2.44 1.62 Frontal sx
50 M 92.46 0.79 Temporal dx
39 M 79.25 32.92 Parietal dx
64 F 33.82 43.21 Parietal dx
28 F 25.64 26.24 Temporal sx
55 F 12.47 0.32 Temporal sx
31 M 19.81 1.95 Temporal sx
52 F 50.12 4.37 Temporal sx
71 F 17.98 0.28 Frontal cortex
62 M 20.41 0.03 Total cortex
50 M 60.72 0.76 Occipital cortex
52 M 45.11 0.45 Total cortex
68 F 25.30 0.23 Frontal cortex
Table 3: Age, gender, mRNA expression values (in femtograms), and anatomical location of normal brain specimens.
Age Sex EGFR ADAM17 HB-EGF PTEN MMP9 Location
71 F 32.58 10.74 14.84 17.98 0.28 Frontal cortex
62 M 16.70 12.76 10.41 20.41 0.03 Total cortex
50 M 57.94 18.35 30.41 60.72 0.76 Occipital cortex
52 M 25.74 13.87 28.55 45.11 0.45 Total cortex
68 F 46.98 17.20 7.60 25.30 0.23 Frontal cortex
Table 4: MMP9 and PTEN absolute quantitative expression in
diﬀerent human normal (NHA) and glioma (PRT-HU2 and U138-
MG) cell lines. Expression is indicated in femptograms.
Cell line MMP9 PTEN
NHA 0.59 117.97
PRT-HU2 0.56 45.62
U138-MG 3.09 4.08
overexpression and loss or mutation of the Phosphatase and
TEN sin homolog deleted from chromosome 10 (PTEN)
tumor suppressor protein [6]. The PTEN phosphatase
reduces the levels of the second messenger phosphatidyli-
nositol 3,4,5-triphosphate (PI3K) and regulates the activity
of the downstream PI-3K/AKT- and mammalian target of
rapamacyn- (mTOR-) dependent pathways [7]. Notably,
PTEN functional loss or mutation is present in 60%–70%
of high-grade gliomas and is associated with malignant
phenotypic changes such as migration capability, probably
by modulation of FAK activity [8]. Moreover, since PTEN
loss appears to accelerate the formation of high-grade
gliomas [6], it could potentially represent a valid candidate
gene to discriminate between high- and low-grade gliomas.
One typical feature of glioblastoma is its high ability
to disseminate and spread to distant brain areas. Proteases
expressed by glioma cells appear to play a signiﬁcant role in
these processes because selective matrix metalloproteinases
like MMP2 or MMP9 degrade the extracellular environment
in order to facilitate tumor cell growth and migration.
Expressionoftheseproteasesappearstoincreasewithglioma
grade and in vitro studies showed that modiﬁcations of their
expression levels resulted in altered migratory properties
[9]. Although some previous reports have examined the
expression of EGFR [3], PTEN [10], HB-EGF [9], ADAM17
[11], and MMP9 [12] in astrocytoma samples, at present
the transcriptional expression of these ﬁve EGFR pathway-
related genes has not yet been simultaneously investigated in
glioma.
Therefore,inthisstudywehaveevaluatedbyquantitative
Real-time PCR the expression of ADAM17, EGFR, HB-EGF,
PTEN,a n dMMP9 mRNAs in a panel of glioblastoma and
anaplastic astrocytomas specimens and cell lines, and we
have ﬁnally compared them to normal control samples to
ascertain whether these expression proﬁles might provide
additional tools in glioma diagnosis and in tumor subtypes
identiﬁcation.
2.MaterialsandMethods
2.1. Human Biopsy Samples. Biopsy samples, obtained from
Azienda Ospedaliera Universitaria di Parma (Parma, Italy)
after informed consent of the patients, were placed in ice-
cold Trizol reagent (Invitrogen, Paisley, UK) and immedi-
ately processed for RNA extraction. Sections of samples were4 Journal of Biomedicine and Biotechnology
Table 5: GeneBank accession numbers, PCR primer sequences, and products.
Gene Accession number PCR primer sequences (5 -3 ) PCR product (bp)
EGFR NM 005228 AGGAAGAAGCTTGCTGGTAGC 88
CTCTGGAAGACTTGTGGCTTG
ADAM17 NM 003183 CAAGTCATTTGAGGATCTCACG 96
TCTTTGCTGTCAACACGATTCT
HB-EGF NM 001945 GCCTAGGCGATTTTGTCTACC 119
GCCCAACCTCTTCTGAGACTT
PTEN NM 000314 CAGCAGTGGCTCTGTGTGTAA 98
ATGGACATCTGATTGGGATGA
MMP9 NM 004994 AAAGCCTATTTCTGCCAGGAC 105
GCACTGCAGGATGTCATAGGT
independently histologically and morphologically evaluated
by diﬀerent neuropathologists and classiﬁed as grade IV
(glioblastoma multiforme) or grade III (anaplastic astro-
cytoma), according to WHO guidelines [13]. Clinical data
of glioblastoma patients are reported in Table 1, and they
included 19 females and 18 males (age range 23–84 years,
mean 57.8 ± 13.3). The anaplastic astrocytoma patients
(Table 2) included 7 males and 9 females (age 28–68, mean
50.7 ± 13.9). Total RNA samples extracted from human
postmortem normal brain (NB) cortical regions, as reported
in Table 3, were purchased from Ambion (Foster City, Calif,
USA): these included 2 females and 3 males (age range 50–71
years, mean 60.6 ±9.3).
2.2. Cell Lines. Normal human astrocytes (NHAs) were
purchased from Cambrex (East Rutherford, NJ, USA) and
cultivated in the speciﬁc astrocyte AGM medium (Cam-
brex) according to the manufacturer’s speciﬁcations. Human
glioma cell line U138-MG, derived from a glioblastoma
multiforme patient and widely employed, was purchased
from ATCC (Rockville, Md, USA); PRT-HU2 cells, pre-
viously described [14], were analogously derived from a
glioblastoma multiforme patient. U138-MG and PRT-HU2
cells were cultivated in D-MEM medium supplemented with
10% FBS, 100units/mL penicillin, 0.1mg/mL streptomycin,
and 1% L-glutamine (Invitrogen, Paisley, UK).
2.3. Real Time Quantitative PCR. Total RNA was
extracted as previously described [14]a n da c c u r a t e l y
quantiﬁed using spectrophotometric and ﬂuorimetric
(Quant-it RNA Assay, Invitrogen) approaches. The
gene-speciﬁc primers were designed using the “Primer3
input” software (http://frodo.wi.mit.edu/primer3/), and
their speciﬁcity was veriﬁed using the Primer-BLAST
software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/
index.cgi?LINK LOC=BlastHome/). GeneBank accession
numbers of the ﬁve genes examined, their respective primer
pairs sequences, and PCR products lengths were reported in
Table 5. Quantitative Real-time PCR analysis was performed
as previously described [14]. For the absolute quantiﬁcation
of speciﬁc cDNA, standard curves were derived using
diﬀerent concentrations of EGFR, ADAM17, MMP9, HB-
EGF,a n dPTEN DNA-sequenced templates, prepared by
reamplifying the PCR puriﬁed products obtained from Real-
time PCR. The second derivative maximum method in the
Light Cycler software was used to calculate the crossing point
(Cp) value, and the concentrations of each speciﬁc cDNA
were determined. All results were quantitative expressed in
femtograms (fg) of cDNA, normalized to a total RNA input
of 1 microgram.
2.4. Statistical and Bioinformatics Analysis. All results were
expressed as mean ± standard deviation of each biopsy
specimens, assayed in duplicate. The Instat v.3 software
(GraphPad Software Inc., Mass, USA) was used for the
statistical analysis of diﬀerences in gene expression between
groups by one-way ANOVA and for the analysis of corre-
lations among gene expression proﬁles, using the Pearson
coeﬃcient r.AP-value less than .05 was considered sta-
tistically signiﬁcant. The dendrogram and the classiﬁcation
tree analysis were performed using the Orange data mining
software (http://www.ailab.si/orange/). In particular, for the
hierarchical clustering analysis, an Euclidean distance matrix
was adopted. Statistical trends were obtained from the
PTEN and MMP9 average quantitative expression within
normal control, anaplastic astrocytoma, and glioblastoma
multiforme diagnostic classes, using the Excel software
with an exponential setting (Microsoft Word Package 2003,
Redmond, Wash, USA).
3. Results
The mRNA expression of the investigated genes of glioblas-
toma multiforme and normal brain specimens were analyti-
cally reported in Tables 1 and 2 a n dd e p i ct e di nF i g u r e s1 and
2. On the basis of their expression patterns in glioblastoma
and using the mean values of normal samples as cut-
oﬀ, the investigated genes were roughly classiﬁed in three
diﬀerent subgroups, the ﬁrst including ADAM17, HB-EGF,
and PTEN, whose average levels in glioblastoma were below
the controls, the second comprising MMP9, whose majority
of values in glioblastoma specimens were higher than in
controls and, ﬁnally, the last one constituted by the EGFR
gene, displaying the widest variation and data dispersion
(Figure 1).Journal of Biomedicine and Biotechnology 5
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Figure 1:ThemRNAexpressionlevelsof(a)ADAM17,(b)HB-EGF,(c)PTEN,(d)MMP9,and(e)EGFRin37humanglioblastomasamples
(GBM) and in ﬁve normal brain cortex samples (NB). Horizontal lines represent the mean values. ∗P<. 002, ∗∗P<. 0001.
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Figure 2: The mRNA expression levels of PTEN and MMP9 in 16
human grade III astrocytoma samples (AA). Bold horizontal lines
representthemeanvalues,andthinlinesrepresentthemeannormal
brain cortex samples (NB) values.
T h em R N Al e v e l so fADAM17 metallo-protease in
glioblastoma (mean 5.88fg ± 5.71) were signiﬁcantly lower
(P<. 002) than in controls (14.51fg ± 3.15). In particular,
in 33 out of 37 cases (89.19%), ADAM17 expression was
lower than in control samples. For HB-EGF gene, although
31 out of 37 (83.78%) glioblastoma samples displayed
mRNA levels lower than controls, statistical analysis revealed
that the diﬀerence between controls (18.36fg ± 10.52) and
glioblastomaspecimens(10.96fg±10.13)wasnotstatistically
signiﬁcant (P<. 434).
PTEN expression pattern showed statistically lower
mRNA levels in all glioblastoma samples compared to
controls. Notably, the highest PTEN expression level among
all glioblastoma had a quantitative expression (15.05fg) that
was less than 50% of the mean controls values (33.91fg),
withacontrolnormalizedratiorangingfrom2.25to82.72fg.
As expected, there was a very high statistically signiﬁcant
diﬀerence (P<. 0001) of PTEN mRNA expression between
glioblastoma (3.86fg±3.15) and controls (33.91fg±18.44).
MMP9 was overexpressed in the majority of glioblas-
toma specimens (72.22%) and, furthermore, in a subgroup
of 24 cases (64.86%) the expression level was at least
twofold higher than in controls, with a control normalized
ratio within this subgroup ranging from 1.74 to 123.71fg.
However, the mean expression level of MMP9 mRNA in
glioblastoma (5.11fg ± 8.78) was not signiﬁcantly diﬀerent
(P = .238) from control samples (0.35fg ±0.27).
EGFR mRNA transcript levels, due to their amplitude in
expression, were arbitrarily divided into two glioblastoma
subgroups. The former, ranging from 0.77 to 95.25fg,
included 25 samples (67.63%); the latter, had EGRF absolute
quantitative values ranging from 150.97 to 2562.92fg. All
control samples showed EGFR expression values below
100fg, with a mean value of 35.98fg ± 16.51. It was evident
that for EGFR there was no statistically signiﬁcant diﬀerence
(P<. 371) between glioblastoma (247.60fg ± 517.45) and
control samples (35.98fg ±16.52).
Within glioblastoma samples, a highly statistically sig-
niﬁcant negative correlation (P<. 0001; Person coeﬃcient
r =− 0.776) was related to the expression of PTEN and
MMP9;i nad i ﬀerent manner, a statistically signiﬁcant
positivecorrelation(P<. 05;Pearsoncoeﬃcient,r = 0.9221)
was scored for the same genes within the control samples.
The inverse correlation found between PTEN and MMP9
mRNA expression in glioblastoma compared to control
samples, prompted us to investigate whether this correlation
was also detectable in other glioma grades of malignancy.
Therefore, PTEN and MMP9 expression, reported in Table 2
and illustrated in Figure 2, was investigated in 16 histological
conﬁrmed anaplastic astrocytoma specimens, previously
classiﬁed as WHO grade III. In these samples, PTEN
mRNA normalized quantitation (29.72fg ± 31.62) was not
signiﬁcantly diﬀerent from control (P = .792), but this
value was signiﬁcantly higher compared to glioblastoma
(P<. 0001). MMP9 expression (13.60fg ± 17.28) was
neither signiﬁcantly diﬀerent from the control (0.35fg ±
0.27, P = .113) nor from glioblastoma specimens (P =
.103). Notably, no statistically signiﬁcant correlation (P =
.709) was found between the mRNA levels of these two
genes in anaplastic astrocytoma samples. Diﬀerently from
glioblastoma, no inverse correlation in PTEN and MMP9
expression was found comparing anaplastic astrocytoma and
control samples (Pearson coeﬃcient, r = 0.127).6 Journal of Biomedicine and Biotechnology
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Figure 3: Dendrogram comparing PTEN and MMP9 absolute quantitative expression. Absolute quantiﬁcations are expressed in
femtograms, as reported in Materials and Methods. WHO grades of malignancy (III, IV) and healthy brain control (C) specimens are
indicated. Glioblastoma multiforme subgroups IV-a, including the majority of glioblastoma specimens, and IV-b, described in Results, are
highlighted. The box (∗) indicates subgrouping of patients sharing similar tumor anatomical localization (i.e., temporal). Subgroups IV-a
and IV-b have a diﬀerent and signiﬁcant distribution of age-class III patients (>61 years, P<. 01 Anova-one way).
Then, PTEN and MMP9 mRNA levels were compara-
tively examined in two diﬀerent human established glioblas-
toma cell lines (PRT-HU2 and U138-MG) and in a primary
culture of embryonic normal human astrocytes (NHA), as
shown in Table 4. In these cells, PTEN mRNA levels were
much variable comparing to MMP9 expression; similarly
to the above examined control samples, normal astrocytes
exhibited the highest PTEN expression.
We next exploited if PTEN and MMP9 expression might
be more tightly related to the glioma tumor progression.
To this purpose, diﬀerent bioinformatics analyses were
performed using the experimental data set reported in Tables
1, 2, 3,a n d4 and considering the WHO grading of the
specimens. We therefore performed hierarchical clustering,
a standard unsupervised learning method [10] of the tumor
specimens.TheWHOgradingwassimultaneouslycompared
to PTEN and MMP9 expression values, to identify homoge-
neous clusters. As reported in the dendrogram of Figure 3,
diﬀerent groups of samples were created, according to the
above mentioned criteria. Using Euclidean distances, WHO
grades IV and III and normal control samples were roughly
classiﬁedintodiﬀerentclusters.Ofnote,amajorsubsetofthe
glioblastoma specimens was identiﬁed (Figure 3,s u b g r o u p
IV-a), showing the lowest and almost similar levels of both
PTEN and MMP9 transcripts; the remaining glioblastoma
samples clustered within subgroup IV-b. The association
of tumor anatomical localization and age of the patients
with the levels of PTEN and MMP9 expression was also
investigated. According to the clinical data (Tables 1–3), ages
of the patients were divided into three classes (i.e., I, 20–40;
II, 41–60; III, >61 years): as reported in the dendrogram,
the age-class III patients exhibited a statistically signiﬁcant
diﬀerence in distribution between subgroups IV-a and IV-b
(P<. 01, Anova one-way). Diﬀerently, no clear associations
between levels of PTEN and MMP9 expression and tumor
localization were highlighted, with the exception of a single
cluster of four class-III patients with a temporal tumor
localization within subgroup IV-a.Journal of Biomedicine and Biotechnology 7
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Figure 4: Classiﬁcation tree derived from the combined measurement of PTEN and MMP9 quantitative expression. At each root, diagnostic
classes are divided following the absolute quantiﬁcation and expressed in femtograms. Probabilities values (P)f o rt h ed i ﬀerent classes are
reported.
Then, a classiﬁcation tree was produced, evaluating the
performance of PTEN and MMP9 expression in predicting
roots characterized by diﬀerent WHO malignant grades; as
reported in Figure 4, 53 out of 58 total samples, correspond-
ing to 53 instances (i.e., 91.3%) ﬁtted with the classiﬁcation
tree; in detail, all grade IV samples had PTEN normalized
expression values below a quantity of 19.195fg (37/37
instances, P = .905), while the large majority of control
(80% of the total C instances) and anaplastic astrocytomas
samples (70%, P = .636) were grouped with PTEN >
19.195fg; in this subgroup, to further diﬀerentiate control
and anaplastic astrocytomas, MMP9 < 0.775fg clustered all
control instances (P = 1.000).
Nomogram analysis, performed within the same data set
a n dr e p o r t e di nFigure 5 conﬁrmed that PTEN and MMP9
expression analysis might be particularly helpful in the
identiﬁcation of anaplastic astrocytoma specimens having a
95%ofprobability(P(gradeIII) = .95)tocorrectlyclassifythese
samples, in correspondence of MMP9-normalized expres-
sion value of 19.195fg, independently of PTEN expression
level. Nomograms analysis with control and glioblastoma
as target diagnostic classes showed less statistical signiﬁcant
probabilities (P(control) = .60 and P(gradeIV) = .55).
To further elucidated if PTEN and MMP9 expression
had an expression trend that reﬂected the malignant grade
of the specimens (i.e., normal, anaplastic astrocytomas,8 Journal of Biomedicine and Biotechnology
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Figure 5: Nomogram analysis of PTEN and MMP9 expression within the diﬀerent WHO grades of malignancy (III, IV) of the astrocytomas
specimens. Points and total points axes indicate the points attributed to each variable value and the sum of the points for each variable,
respectively. P axes indicate the predicted probability that relates PTEN or MMP9 quantitative expression to each WHO tumor malignancy
grade.
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Figure 6:Statisticaltrendsof PTEN (blackdottedline)andMMP9 (greydottedline)expressionincontrol(C),anaplasticastrocytomas(III)
and glioblastoma multiforme (IV) specimens (Panel A), and in normal human astrocytes (NHA), glioma PRT-HU2 (HU2), and U138-MG
(U138) cells (Panel B). Trends are calculated using average quantitative expression of PTEN and MMP9, and adopting exponential (Espo)
models of prediction as follows: PTEN (C, III, IV average expression samples), y = 2148e−1.29x; MMP9 (C, III, IV), y = 83716e0.50x; PTEN
(NHA, HU2, U138), y = 118596e−1.82x; MMP9 (NHA, HU2, U138), y = 42439e1.40x.
and glioblastoma multiforme), a statistical trend analysis
was performed (Figure 6); the analysis reported in Panel A
showed that PTEN and MMP9 diﬀerences in their normal-
ized expression clearly decreased following the malignant
glioma grading, with the lowest values corresponding to
glioblastoma multiforme specimens; similarly, the trend
analysis, reported in Figure 6 Panel B, highlighted that,
within the investigated cell lines, normal human astrocytes
exhibited the largest diﬀerences in PTEN and MMP9
expression levels, while, on the contrary, U138-MG cells,Journal of Biomedicine and Biotechnology 9
isolated from a glioblastoma multiforme patient, showed
nearly coincident PTEN and MMP9 expression values; the
glioblastoma derived PRT-HU2 cell line showed values of
PTEN and MMP9 expression trends, intermediate between
NHA and U138-MG.
4. Discussion
The new challenge in cancer biology is to move from one
purely morphological classiﬁcation of cancer to one that
is based on the integration of histological and molecular
criteria [15]. Among several cancer speciﬁc investigated
genes, the epidermal growth factor receptor (EGFR)p l a y s
a pivotal pathological role through the activation of down-
stream intracellular signalling pathways that can directly
modulate cell proliferation, metastasis, and angiogenesis
[8]. Glial tumors, in particular, due to processes of gene-
ampliﬁcation or mutation, showed altered EGFR-related
functional pathways [3]. Within this context, in order to ﬁnd
clinically relevant correlations between gene expression and
tumor malignant progression, a cohort of glioma specimens
was analyzed for the expression of several genes, that is,
ADAM-17, PTEN, MMP9, EGFR,a n dHB-EGF, indirectly
involved in the EGFR-dependent signaling pathway, In fact,
the concurrent measurement of the transcript levels of the
diﬀerent genes could potentially represent a useful tool to
identify a dysregulation of receptor activation or of down-
stream signaling pathways or might also suggest functional
links between these genes in pathological conditions [16].
Comparing a cohort of glioblastoma specimens and con-
trols, only two genes,A D A M - 1 7and PTEN, had expression
levels that signiﬁcantly changed between the two WHO
classes; on the contrary, considering the expression of each
transcript separately, we did not elucidate any association
between clinical status and EGFR, HB-EGF,a n dMMP9
expression proﬁles. In particular, the wide range of variation
for the EGFR gene, found in glioblastoma specimens, was in
partial agreement with previous studies carried out in glial
tumor samples [8]. In general, nearly 50% of glioblastoma
multiforme cases express ampliﬁed EGFR, and about 40%
of them also express the constitutively activated mutated
EGFRvIII isoform [11]. Since the primers we used in
our experiments did not discriminate between EGFR and
EGFRvIII, it is very likely that the EGFR mRNA levels found
in our samples reﬂected the combined contribution of both
the transcripts.
Since chemotherapic treatments enhance the EGFR-
mediated proliferative responses via an increased HB-EGF
expression and shedding [17], previous studies have sug-
gested a prominent role for HB-EGF in tumorigenic pro-
cesses.Infact,ingliomacelllines,theinducibleexpressionof
EGFRvIII can enhance HB-EGF expression and can activate
EGFR-dependent pathways via a positive feedback autocrine
loop [18]. The only previous published study, based on
a semiquantitative assessment by Northern blot analysis,
found an increased expression of HB-EGF in glioblastoma
compared to control samples [9]. On the opposite, our
data seemed to suggest that HB-EGF is not upregulated in
glioblastoma; however, our results agreed with microarray
gene expression proﬁles studies that showed no signiﬁcant
diﬀerences in HB-EGF expression between glioblastoma and
control samples [19].
Recent mounting evidence showed that the expression
of MMP9 might play a critical role in brain neoplastic
tissueinvasion, metastasis, andangiogenesis [12]. Even if not
completely statistically supported, our ﬁndings were in good
agreement with a previous work showing an upregulation of
MMP9 mRNA levels in glioblastoma compared to controls
and suggesting a close relationship between MMP9 expres-
sion and tumor malignant progression [12].
Although ADAM17 expression has been reported in
normalhumanbraintissueandincelllines[5],itsexpression
at mRNA level has been poorly investigated in brain tumors.
Functional studies in U373-MG glioma cells have demon-
strated that cannabinoids induced cell proliferation through
a two-step mechanism involving ADAM17-mediated shed-
ding of proHB-EGF and subsequent EGFR stimulation [5].
Our ﬁnding that ADAM17 mRNA levels in glioblastoma are
statistically lower compared to controls is in contrast with
a previous work that reported an increased expression of
ADAM17 in glioblastoma specimens [20]. This might reﬂect
diﬀerences in tumor sampling or a consequence of glioblas-
toma multiforme cellular and molecular heterogeneity.
Ourﬁndingshowingthatglioblastomaexpressedstatisti-
cally signiﬁcant lower PTEN mRNA levels compared to con-
trol samples conﬁrmed previous reports [21], showing that
PTEN expression variations were detectable only in a low
fraction of anaplastic astrocytoma and were almost absent in
low-grade brain tumors and controls. Taken together, these
observations strengthen the hypothesis that an impairment
of PTEN expression, together with a consequent aberrant
activity of the PI3K-dependent pathway, might represent a
typical hallmark of glioblastoma multiforme. A functional
conﬁrmation of this hypothesis was that, in a mouse
astrocytoma model with genetic inactivation of the Nf1 and
p53 tumor suppressor genes, the loss of PTEN heterozygosity
and the Akt activation contributed to the brain tumor
malignant progression [6].
Diﬀerentlyfromtheabovementioned investigated genes,
the analysis of PTEN and MMP9 expression, using a combi-
nation of unsupervised and supervised algorithms, provided
interesting results: ﬁrstly, as reported in the dendrogram
analysis, the expression proﬁling derived novel subsets of
astrocytomas. This hierarchically clustering analysis clariﬁed
that tumor classiﬁcation based even on a quantization of
two genes could generate a patient stratiﬁcation, clinically
relevant and more informative than a single conventional
histological classiﬁcation. The PTEN and MMP9 expression-
generated subgroups produced also a diﬀerent distribution
of the patients according to their age: in particular subgroup
IV-a, diﬀerently from IV-b, was enriched in age-class III
patients (i.e., >61 years); this result might suggest that
in glioblastoma multiforme tumor specimens PTEN and
MMP9 expression levels might be partly related with the
elderly of the patients. On the contrary, in anaplastic
astrocytoma and in control patients no association between
age-related classes and PTEN/MMP9 expression levels was
evidenced. Furthermore, the originated dendrogram does10 Journal of Biomedicine and Biotechnology
not reﬂect a classiﬁcation of samples according to their
anatomical tumor localization. However, in the light of
the development of new pharmacological treatments, the
identiﬁcation of patient subsets with speciﬁc molecular
signatures within tumor malignancy grades is becoming
more and more relevant [22]. A ﬁner analysis of PTEN
and MMP9 expression was also employed to derive a par-
simonious classiﬁcation tree of the investigated samples into
their tumor malignancy grades. Speciﬁc PTEN and MMP9
expression values signiﬁcantly addressed the specimens into
a speciﬁc diagnostic class, that is, glioblastoma or anaplastic
astrocytomas. However, the signiﬁcance and the sensitivity
of this classiﬁcation might be further reﬁned with the
increasing of specimens and through the identiﬁcation of
novel tumor-diagnostic markers. Basing on the average
expression of PTEN and MMP9, the observed statistical
trends clearly diﬀerentiate the control, anaplastic astrocy-
tomas, and glioblastoma multiforme diagnostic classes; a
similar expression trend for PTEN and MMP9 genes was
documented comparing normal versus astrocytic tumor cell
lines. These results, in particular, reinforced the concept that
anaplastic astrocytomas were intermediate-grade tumors,
showing detectable mitotic activity, absent in low-grade
astrocytomas, but not necrosis and prominent vascular
proliferation, characteristic of glioblastoma multiforme [23,
24].
An additional interesting ﬁnding emerging from our
study was the signiﬁcant negative correlation between PTEN
and MMP9 mRNA expression in glioblastoma multiforme.
Notably, not only was this negative correlation absent in
anaplastic astrocytoma samples, but it was reversed in
controlsamples.ItwasevidentthatdiﬀerencesinPTEN gene
expression mainly account for these correlations because
its levels in glioblastoma were signiﬁcant higher compared
to anaplastic astrocytoma samples, whilst no statistical
diﬀerence was found for MMP9 mRNA levels. The positive
correlation between PTEN and MMP9 in controls is derived
essentially from an overexpression of PTEN rather than a
low expression of MMP9 compared to glioblastoma. The
functional signiﬁcance of these correlations is currently
unknown, and future functional studies aimed at elucidating
possible interplays of these genes in glioblastoma are clearly
warranted. The negative correlation in glioblastoma between
MMP9 and PTEN could imply a functional interplays
between these two genes, as already documented. It has
been reported that PTEN modulates the expression and
secretion of MMP2 and MMP9, thereby modifying tumor
cell invasiveness [9, 25]. Notably, recent reports have clearly
demonstrated that, in glioblastoma, PTEN may regulate
migration via a PI3K-independent pathway [26]. In this
model, the lack or functional loss of PTEN not only poten-
tiates the migration induced by EGFR- and beta-integrin-
dependent pathways but also enhances cell migration via
a still largely unclear mechanism. On this regard, a recent
report suggested that integrins could be a converging point
in the mechanism supporting tumor invasion and migration
of cancer cells with PTEN loss and MMP9 overexpression.
The intrinsic genetic heterogeneity and redundant over-
lapping aberrant signalling transduction pathways underlie
the failure of monotherapies in glioblastoma [8]. Therefore
a sensitive and reliable method to measure gene expression,
such as Real-time PCR, may greatly ameliorate diagnostic
tools and eventually address the pharmacological approach
using multitarget kinase inhibitors or combination of ther-
apies based on multiple single-targeted receptor or intracel-
lular kinase inhibitors. Some researchers have proposed that
the combination of PTEN loss and EGFR hyperfunctionality
could be predictive of the ineﬀectiveness of therapies with
EGFR inhibitors [4] because these two pathways might syn-
ergize to enhance glioblastoma malignancy. This hypothesis
has been elegantly supported by the recent observation that
the pharmacological inhibition of PI3K-alpha and mTOR
augments the antiproliferative activity of the EGFR inhibitor
erlotinib in glioblastoma cell lines [7]. The inverse corre-
lation between PTEN and MMP9 expression reported here
raised the issue whether the concomitant hyperactivation of
the PI3K-alpha and MMP9-dependent pathways might be
instrumentalindevisingorreﬁningcombinedpharmacolog-
ical therapies in glioblastoma. The modest eﬃcacy of mTOR
inhibitors alone in clinical trials was greatly enhanced when
these compounds were administered in combination with
the EGFR inhibitor Geﬁtinib [27]. Although monotherapy
regimens with MMPs inhibitors in clinical trials have been
quite disappointing, the relevance of MMPs as valid target
has been reevaluated by the recent ﬁnding that the combined
use of MMPs, COX2, and EGFR inhibitors reduced human
breast cancer tumor growth [11]. We therefore speculate that
thepivotalroleofMMPsingliomainvasionandangiogenesis
deserves future in vitro and in vivo experiments using MMP
inhibitors in combination with PI3K inhibitors alone or with
these latter compounds plus EGFR inhibitors.
The analyses of gene expression at transcriptional level
in biopsy tissue samples are instrumental in delineating
abnormal gene expression signature of brain tumors, but
it should be mentioned that these studies suﬀer some
pitfalls and limitations: in particular, the use of supervised
approaches, based on the assumption that the grouping
(i.e., the histological tumor diagnoses) is correct, may not
be a valid assumption for all the clinical cases examined;
additionally, the intrinsic heterogeneity of glioblastoma,
together with the presence of nontumor cells in the samples,
probably accounts for the variability found in transcripts
levels and may represent a critical factor and a limitation
in the interpretation of our results. From a technical point
o fv i e w ,am a i nd i ﬀerence of our contribution, compared
to other reports, deals with the criteria adopted to express
transcript levels in the investigated specimens. The majority
of clinical gene expression proﬁle studies performed by Real-
time PCR normalized data using an internal housekeeping
gene as a reference, but great caution in choosing this
normalizationmethodisnecessaryespeciallywhenanalyzing
tumor biopsy samples [28]. The tumorigenic process itself,
via genomic mutations or ampliﬁcations, could induce
modiﬁcations of housekeeping genes levels [29], and hence
the choice of unreliable housekeeping genes may lead to
interpretation errors and bias in experimental results [30].
Our attempts to use GAPDH, ACTB,a n dHPRT as reference
genes were unsuccessful due to the great variations amongJournal of Biomedicine and Biotechnology 11
all the samples (data not shown); therefore, we decided to
express gene expression as absolute amount of femtograms
(fg) of transcripts, normalized to the total amount of RNA
employed, through accurate quantiﬁcation using the combi-
nation of spectrofotometric and ﬂuorimetric approaches.
In conclusion, the combined analysis of the transcripts
of PTEN and MMP9 genes in biopsy specimens could
represent a reliable diagnostic and prognostic marker of
human glial tumor. Further epidemiological and functional
in vitro studies are required to establish the reliability of
PTEN andMMP9genesaspossiblevalidmoleculartargetsin
the pharmacological strategies aimed at controlling human
glioma malignant progression.
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